We came across a bullish thesis on Catalyst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on CPRX. Catalyst Pharmaceuticals, Inc.'s share was trading at $22.96 as of January 15th. CPRX’s trailing and forward P/E were 13.43 and 10.34 respectively according to Yahoo Finance.
[caption id="attachment_522188" align="aligncenter" width="750"]Catalyst Pharmaceuticals (CPRX) is positioned as a leading rare-disease biopharma with a focused dual-pillar...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.